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ABSTRACT
Objectives: To explore stakeholders’ perceptions of
decision aids designed to support the informed
consent decision-making process for randomised
controlled trials.
Design: Qualitative semistructured interviews.
Participants were provided with prototype trial decision
aids in advance to stimulate discussion. Interviews
were analysed using an established interpretive
approach.
Participants: 23 stakeholders: Trial Managers (n=5);
Research Nurses (n=5); Ethics Committee Chairs
(n=5); patients (n=4) and Clinical Principal
Investigators (n=4).
Setting: Embedded within two ongoing randomised
controlled trials. All interviews conducted with UK-
based participants.
Results: Certain key aspects (eg, values clarification
exercises, presentation of probabilities, experiences of
others and balance of options) in the prototype
decision aids were perceived by all stakeholders as
having a significant advantage (over existing patient
information leaflets) in terms of supporting well
informed appropriate decisions. However, there were
some important differences between the stakeholder
groups on specific content (eg, language used in the
section on positive and negative features of taking part
in a trial and the overall length of the trial decision
aids). Generally the stakeholders believed trial decision
aids have the potential to better engage potential
participants in the decision-making process and allow
them to make more personally relevant decisions about
their participation.
Conclusions: Compared to existing patient
information leaflets, stakeholders perceived decision
aids for trial participation to have the potential to
promote a more ‘informed’ decision-making process.
Further efforts to develop, refine and formally evaluate
trial decision aids should be explored.
INTRODUCTION
There is an ethical requirement to obtain
informed consent from potential participants
before they are enrolled in a randomised
controlled trial (RCT).1 2 As part of the
informed consent process, potential trial
participants are provided with written infor-
mation about the trial often in the form of a
participant information leaﬂet (PIL).3 The
information included in PILs is largely
guided by the Declaration of Helsinki, the
International Conference on Harmonisation
and Good Clinical Practice (ICH GCP) and,
in the UK, by national guidance such as the
National Research Ethics Service (NRES).2–4
As outlined by this guidance the PIL should
include largely fact-based information about:
the purpose of the trial; procedures; inter-
ventions; possible risks and beneﬁts; sources
of ﬁnance; conﬂicts of interest; and the
researcher’s afﬁliation.3 4
Existing PILs may be suboptimal; research
has shown that some trial participants (both
those considering participation and those
actively enrolled) fail to understand key
aspects of trial rationale or process.5 6 A
range of studies have tested ways to improve
Strengths and limitations of this study
▪ This study is the first to explore, and evidence,
the potential of a decision aid to support
decision-making for participating in a rando-
mised controlled trial from the perspectives of a
range of stakeholders, including: patients; Trial
Managers; Research Nurses; Clinical Principal
Investigator; and Ethics Committee Chairs.
▪ Compared to existing patient information leaflets,
this study has shown that trial decision aids
have the potential to better engage potential par-
ticipants in the decision-making process and
allow them to make more personally relevant
decisions about their participation.
▪ All the participants in our study were UK based
and a self-selecting sample and therefore may
hold different views to those in other countries
with different social norms and cultures.
However, these participants can offer thoughtful
and reflective insights into decision aids for trial
participation when reflecting on their own trial
experience including reflection on existing
patient information leaflets.
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information provision in the context of trials.6 These
have tended to focus on the content and structure of
the information and measured outcomes such as under-
standing, recall and trial recruitment.6 While improving
understanding of the trial is important, informed
decision-making about trial participation is complex and
likely to require more than just greater understanding of
fact-based information.6 Furthermore, it has been
argued that PILs are ‘institutionally scripted’ as a means
to obtain ethical approval rather than functioning as a
tool to support potential participants’ decision-making.7
As such, the current conceptualisation of ‘informed
consent’ (largely as understanding of information) and
how it is enacted (through signing of a consent form)
may be overly narrow and require broadening to con-
sider the importance of deliberation and determination
in the decision-making process for trial participation.8 9
Evidence from the treatment and screening decision-
making literature has highlighted that certain key items
are important for making ‘good’ decisions.10 11 For
example, being able to consider alternative options (in
the context of trial participation this may be another
intervention or may be usual care), making trade-offs
and evaluating potential outcomes of the decision and
consideration of what those outcomes mean personally
for that individual. These items, and others, are often
included in decision aids, which actively encourage
people to participate in decisions about treatment that
involve weighing up associated beneﬁts and harms often
when there is clinical uncertainty.10 Decision aids have
been developed for a variety of treatment and screening
decisions and have been shown to positively inﬂuence
several aspects of decision-making.10 The items identi-
ﬁed as being important for good decision-making are
largely lacking from existing PILs for trial participa-
tion,12 further supporting the contention that existing
PILs do not function well as decision-making tools.12
The very few published studies that have explored the
use of decision aids, or components of them, in the
context of trial participation decisions have shown some
promise.13–15 For example, compared to existing PILs,
decision aids for trial participation have been shown to
improve understanding while not increasing anxiety13
and resulted in low levels of decisional conﬂict and high
levels of satisfaction.14 Although encouraging, these
studies have solely focused on trial participants’ percep-
tions and have not explored other stakeholders’ opi-
nions. While trial participants perspectives remain key,
replacement of or any amendments to existing PILs
would require buy-in from an additional range of stake-
holders, such as: developers (eg, Trial Managers); deli-
verers (eg, Research Nurses and Clincal Principal
Investigator); and approvers (eg, Ethics Committees).
This buy-in is critical to ensuring that trial decision aids
are as effective as they can be (ie, act as a decision
support tool to facilitate meaningful conversations that
encourage informed decision-making), are implementa-
ble and used as intended. Although treatment and
screening decision aids have been shown to be efﬁca-
cious, the main barriers to their effectiveness in a real
world setting are a lack of implementation and ﬁdelity of
use often as a result of a lack of buy-in at inception from
stakeholders.16 17 Furthermore, previous studies on trial
decision aids have not explicitly explored perceptions of
the ‘new’ content (ie, features to improve decision-
making), which deﬁne decision aids as different to exist-
ing PILs.
The study reported in this manuscript forms part of a
larger programme of work that aimed to systematically
develop and pilot (through interviews reported here)
prototype trial decision aids. The prototype decision
aids were developed through an iterative process
informed by the MRCs framework on development of
complex interventions.18 The process began with estab-
lishing the current evidence on the effectiveness of deci-
sion aids for supporting decisions about RCT
participation.19 Next a Delphi study was conducted, with
a range of stakeholders, to identify key items for inclu-
sion,20 followed by an evaluation of existing PILs using a
tool (that contains items assessing key features of ‘good’
decision-making) to identify areas that were lacking,12
drafting of protoype decision aids (informed by previous
stages), followed by rounds of revision within the study
team. We then undertook an in-depth qualitative study
to explore stakeholders’ views and perspectives on the
speciﬁc content of the prototype decision aids and their
potential to improve the informed consent process for
RCTs the qualitative study reported in this paper.
METHODS
Development of the prototype trial participation
decision aids
Prototype decision aids were developed for two on-going
RCTs. The ﬁrst was a trial comparing two surgical proce-
dures for treatment of haemorrhoids (ISRCTN
80061723, date of registration 8 March 2010); and the
other a drug trial comparing two active drugs and a
placebo for treatment of ureteric stones (ISRCTN
69423238, date of registration 18 November 2010). These
RCTs were identiﬁed from the portfolio of RCTs
managed by the Centre of Healthcare Randomised Trials
(CHaRT) at the University of Aberdeen. The content of
the prototype decision aids was developed through the
iterative process outlined above. The prototype decision
aids were enhanced by a graphic designer, at the
University of Aberdeen, to improve the visual impact of
the tools. The tools were presented as A5 booklets which
could be printed or read as a PDF document.
Exploration of stakeholders’ perceptions of trial
decision aids
An open-ended topic guide was developed to elicit
accounts of participant’s view of the prototype decision
aids (see online supplementary additional ﬁle 1). The
topic guide was informed by literature on content items
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for decision aids and explored the key differences
between decision aids and existing PILs.11 12 Moreover,
items identiﬁed as contentious in earlier work20 were
also further explored (eg, use of experiences of others).
The guide, and subsequent analysis, were organised
around views of existing patient information leaﬂets;
views about the prototype decision aids with speciﬁc
exploration of their potential to support the decision-
making process. Semistructured interviews were con-
ducted with different stakeholder groups (including
patients, Trial Managers, Research Nurses, Ethics
Committee Chairs and Clinical Principal Investigators
involved with both trials) to explore perspectives about
the use of decision aids in a trials context.
Sampling and recruitment
Potential participants from the Trial Manager, Research
Nurse and Ethics Committee Chair stakeholder groups
were identiﬁed through email list serves (Trial Managers:
UK Clinical Research Collaboration Trial Managers list-
serv (n=501); Research Nurses: Scottish Research Nurse
and Coordinators Network listserv (n=198); Ethics
Committee Chairs: National Research Ethics Service com-
mittee chair listserv (n=88)). Patients who would be eli-
gible for each RCT were identiﬁed and contacted by a
Research Nurse working at the lead site for each of the
RCTs (n=20). Clinical Principal Investigators for both of
the RCTs were sent an email invite and asked to respond
to the lead researcher (KG) to express interest (n=40).
Prospective participants were sent a letter of invite with a
slip to return, or email response, to express interest.
Interested participants were sent full information about
the study (in the form of a participant information
leaﬂet), and a consent form and were provided with an
opportunity to discuss the research project and have any
questions answered before making a decision. Ethics
Committee Chairs, Clinical Principal Investigators,
Research Nurses and Trial Managers who were recruited
for interview were sent a copy of both decision aids to
review. Recruited patients were only sent the decision aid
relevant for their condition. Recruited participants were
given the choice of a face-to-face or telephone interview.
All participants provided written consent.
Data collection
One author (KG) conducted the interviews between
April 2012 and July 2012. Only one patient participant
chose a face-to-face interview, which was conducted at
the University of Aberdeen as agreed by the participant
and the researcher, all other participants requested tele-
phone interviews. Interviews were audio recorded, tran-
scribed verbatim and anonymised. At the start of the
interviews, participants were encouraged to provide
their views and perspectives on existing patient informa-
tion leaﬂets for clinical trials and discuss their experi-
ences of participating in clinical trials or reviewing
clinical trial information, as appropriate. All participants
were then asked about their views of the prototype
decision aids and how they might, or might not, support
a decision about trial participation (see online supple-
mentary additional ﬁle 1).
Data management and analysis
A thematic content analysis of the transcripts was con-
ducted. An established interpretive approach was used
whereby following familiarisation with the transcripts, a
priori and emergent themes were identiﬁed, discussed
and agreed by the research team.21 As many of the inter-
view questions were developed around predetermined
themes of interest (ie, those relating to speciﬁc content
and purpose of trial decision aids11) there were not
many emergent themes identiﬁed. However, the
meaning and importance attached to each of the prede-
termined themes was emergent. Two authors (KG and
ZS) independently reviewed transcripts and documented
the major emerging themes. A thematic framework was
subsequently generated, and agreed through discussion
with all authors, which detailed codes for labelling
textual data related to the major themes and subthemes.
Codes with speciﬁc relevance to decision aids (and items
which deﬁne them as being distinct from existing PILs)
were used as a priori codes for key parts of the interview
transcripts.11 Transcripts were subsequently coded by
one author (KG), in which the thematic framework was
applied systematically to the textual data. This process
was managed through the use of text management soft-
ware (NVivo V.10). This facilitated data organisation
which promoted further analytic consideration through
constant comparison of data both within and across the
stakeholder groups, this was conducted by two authors
(KG and ZS) and identiﬁed key differences between the
groups and identiﬁed consensus on the importance of
the potential of decision aids across all groups. Relevant
quotes representing interviewees’ considerations were
selected to illustrate the results.
Ethical approval
The study was approved by the North of Scotland
Research Ethics Committee 1 (REC Reference Number
09/S0802/105) and National Health Service (NHS)
Grampian Research and Development department
(Reference Number 2009HS002). All interview partici-
pants provided their signed consent, which included
consent for anonymised quotes from their interviews to
be published.
RESULTS
Sample characteristics
Fifty individuals contacted the researcher (23 Trial
Managers; 10 Research Nurses; 8 Ethics Committee
Chairs; 5 patients and 4 Clinical Principal Investigators)
and 23 were interviewed. Response rates varied across
the groups: 5% for Trial Managers; 7% for Research
Nurses; 9% for Ethics Committee Chairs; 25% for
patients (1 subsequently declined participation); and
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10% for Clinical Principal Investigators. In those stake-
holder groups where more participants responded than
were required for interview, participants were sampled
purposively based on afﬁliation with registered UKCRC
clinical trials units and further stratiﬁed for geographic
location. The number of participants in each group was
decided based on a predetermined judgement that each
group should contain a similar number and be
informed by the numbers interviewed in the patient
group (n=4). The interviews ranged from 40 to 80 min.
We deemed this sample size to be sufﬁcient to identify a
range of experiences and views that would generate a
manageable amount of data for in-depth analysis within
the timescale of this project.22
A brief description of the participants is provided in
table 1. They included 12 women and 11 men, aged
from 35 to 80, who were from the following stakeholder
groups: Trial Managers (n=5); Research Nurses (n=5);
Ethics Committee Chairs (n=5); patients (n=4) and
Clinical Principal Investigators (n=4). Twelve of the
sample had experience of working for an NHS organisa-
tion and seven worked within Universities. Experience
of working in clinical trials (which could be as a
recruiter, a Trial Manager, a reviewer of ethical applica-
tions of trials) ranged from 3 to 20 years. The majority
of the group (n=21) had no previous experience of deci-
sion aids but all stakeholders had previous exposure to
PILs for trials. The themes described below were largely
identiﬁed a priori so as to provide a predetermined
exploration of the key content items that differ between
existing PILs and decision aids for trial participation.
Owing to the predeﬁned areas of importance for investi-
gation informing the topic guide, all themes were dis-
cussed by all stakeholder groups but the extent to which
their opinions converged differed between groups and
across themes.
General impressions of the trial decision aids compared
to existing information leaflets
The majority of stakeholders across all groups perceived
that, in principle, trial decision aids were beneﬁcial and
an improvement on existing PILs. There was a percep-
tion that they provided a ‘balanced’, unbiased picture,
that they were uncomplicated and that they could pro-
actively facilitate more engagement in the decision, com-
pared to existing PILs.
it’s very well balanced and I think that’s really important
because it’s not leading anybody in any one direction.
And I think that’s an excellent part of the whole booklet
itself. (Patient 3)
…I think that they [decision aids] are very, very straight
forward actually, that as I’ve said before the patient infor-
mation leaﬂets are very wordy things and they have a lot of
information to impart to patients and sometimes they will
switch off after the third paragraph. (Research Nurse 1)
…there’s not just an information sheet; there’s a decision
making tool to help the patient make decisions, rather
than it just being a passive thing of read the information
leaﬂet… whereas this is actually making them work
through and think about it, and this is obviously the
biggest change and I do think this would be of a beneﬁt.
(Trial Manager 2)
Although most of the initial perceptions of the deci-
sion aids were positive, some participants, from the
Research Nurse and Clinical Principal Investigator
groups, did feel that the use of a decision aid could
potentially overcomplicate the decision process in this
context by providing more information and potentially
raising concerns.
My concerns were that sometimes people feel that the
patient information sheet alone is onerous, so adding
something else on might actually put some people off….
just that it might increase fear or uncertainty. It almost
makes the decision bigger, by adding in this decision
making tool. (Research Nurse 5)
However, these perceptions were from the minority of
participants within these stakeholder groups, with most
of the group expressing agreement of the improvement
of these decision aids compared to existing methods.
Perception of trial decision aid content
This section of the paper reports the ﬁndings relating to
speciﬁc aspects of the decision aids which are not
Table 1 Characteristics of interviewees
N (%)
Stakeholder group
Trial Manager 5 (22)
Research Nurse 5 (22)
Research Ethics Committee (REC) Chair 5 (22)
Clinical Principal Investigator 4 (17)
Patient 4 (17)
Gender
Male 11 (48)
Female 12 (52)
Age (years)
40 and under 8 (35)
41–60 10 (43)
61 and above 5 (22)
Experience of working in clinical trials (years)*
< 10 7 (37)
≥10 12 (63)
Location (University or NHS)*
University 7 (37)
NHS 12 (63)
Previous experience with decision aids
None 21 (91)
Limited 2 (9)
Experienced 0 (0)
*Patients (n=4) not included in this category.
NHS, National Health Service.
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routinely included in patient information leaﬂets for
trial participation.
Provision of information about positive and negative features
of taking part in the trial
The trial decision aids included information on both
the advantages and disadvantages of both options (par-
ticipating in the trial or not) whereas existing PILs gen-
erally only cover issues relating to trial participation.12
There were varied views (largely across and within the
Research Nurse, Trial Manager and Ethics Committee
Chair groups) expressed when participants reﬂected on
whether the information included about positive and
negative features of participating in the trial or not was
balanced. Some recognised this was a new addition to
the standard information and felt the section was well
balanced and would be helpful for potential participants
to make an informed choice about participation.
I think this does just outline the different variables really
that, you know, there are disadvantages about taking part
in clinical studies and there are disadvantages about not.
It’s an interesting new thing as far as I can see, I’ve not
see anything quite that descriptive before. (Research
Nurse 1)
Other participants felt that while the overall concept
of providing information about both options was advan-
tageous, some of the included information about advan-
tages and disadvantages of options could be deemed as
being potentially coercive. This was a view held by most
of the Trial Managers, Research Nurses and Ethics
Committee Chairs.
And I thought that they [sections on advantages and dis-
advantages participating in the trial or not participating]
were quite helpful…. I did think that one of the sen-
tences [You will receive extra personalised care and atten-
tion from Research Nurses by taking part in the trial]
possibly was a bit over-emotive. (Trial Manager 4)
Even though many participants agreed that advantages
and disadvantages about both options should be
included, all of the Ethics Committee Chairs reported
some of the language as potentially inappropriate and
stated that ethics committees would be uncomfortable
with some statements. For example:
I think that there’s quite a lot of emphasis on saying to
people one of the advantages of taking part is that you’ll
get some extra care and attention… Now, in a sense
that’s true given that that is built in to the research pro-
cedure, but certainly the committee, we’re very… we’re
very sensitive to anything that could be taken as an extra
inducement to take part. And I felt that one or both of
these was a bit more emphatic about that and if we’d be
reviewing these as a committee I think we wouldn’t have
been very comfortable with that. (Ethics Committee
Chair 2)
However, patients reported this section to be well
balanced and felt that this section provided information
to illustrate that participating in a clinical trial may
provide access to services (whether treatment or
follow-up) that would not be available outside of the
trial. For example:
…it was honest, it was upfront and I was like…yeah, okay,
you won’t have to do the questionnaires but yeah, you
will get additional care. So there was a little bit of a “We
provide you with a luxury service” or you just get the
MOT when we’re ready for it. So, it was quite a good
inducement to take part. (Patient 3)
Presentation of probabilities
Methods used to present probabilities of outcomes asso-
ciated with interventions across the two prototype trial
decision aids were varied according to reported methods
of good practice for decision aids11 (see ﬁgure 1).
Participants were asked to compare where appropriate.
There was recognition among participants in all stake-
holder groups that presenting complex probabilistic
information to potential trial participants is challenging
and that individuals have varied preferences and under-
standings of this type of information, especially within
the context of clinical trials and the interventions they
are testing.
I think it’s a good way of presenting it [risks] in a differ-
ent way. I think presenting risk as words and as numbers
and as something visual is going to help. I think in the
end it’s still a very hard thing for people to understand,
as I said, at a personal level. (Ethics Committee Chair 3).
A couple of participants, from the Clinical Principal
Investigator and Ethics Committee Chair groups, raised
the importance of placing risk within the context of
familiar activities as an effective way to allow potential
participants to make judgements about the risks they are
willing to take.
…you could say, “This list does look long and worrying
but actually these side-effects don’t occur very often. By
comparison if we listed all the side-effects of paracetamol
these are the things you would be told about” and you
could say very commonly without any problem at all.
(Clinical Principal Investigator 2)
Methods for clarifying and expressing values
The majority of stakeholders across all groups felt that
values clariﬁcation exercises included in the trial deci-
sion aids (see ﬁgure 2), which allow patients to trade-off
positive and negative features of the decision to facilitate
personally meaningful decision-making, were helpful
and that they had the potential to facilitate the decision-
making process.
I mentioned that the pros and cons is very, very good,
I think that that would help a lot of people make deci-
sions and it talks about what would happen to me if I
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didn’t take part in this study as well so that’s something
that we don’t, well we say “Oh well that’s Ok, you’ll just
get the standard course of treatment” is there anything
negative about me not taking part, that’s important to
emphasise that as well. (Research Nurse 4)
A signiﬁcant beneﬁt of values clariﬁcation exercises
that was highlighted by participants was their potential
to allow trial participants to make personally relevant
decisions by weighing up what matters most to them,
within the context of the clinical trial.
I think it would probably be quite useful just to have that
let them weigh that up, whether they want to take part or
not. (Clinical Principal Investigator 3)
And that’s very powerful, they’re making a decision that
feels to them very fair because they’ve done a weighting
process around it. So I really, really liked this. (Research
Nurse 5)
However, a minority of participants (mainly Trial
Managers) felt that the exercises themselves, or aspects
of them (such as the term ‘worksheets’ and the lengthy
instructions for completion), would not be helpful and
could be perceived negatively.
… I don’t know, it just made me think you know patients
thinks, “Ah worksheets, am I going to have to ﬁll in loads
of stuff?”. (Trial Manager 1)
Yet the patient group all perceived these exercises as
being helpful and beneﬁcial for their decision-making,
acting as a guide to take them through the advantages
and disadvantages of trial participation.
I ﬁnd the little piece at the back, the pros and cons table,
or pros and cons balance graphic, quite useful. It did
help me come to my conclusion, the pros and cons one,
because I answered all the questions and highlighted my
answers. I found that really quite interesting. (Patient 2)
However, one of the patients and participants across
the other stakeholder groups did highlight that there
may be a need for the values clariﬁcation exercise to
provide a ‘score’ or objective decision with regard to
trial participation.
It’s like…there’s not a scoring system, so…big beneﬁt, no
beneﬁt, so I don’t know actually where that would come
out. There’s no—what’s my weighting? (Patient 3).
Structured guidance in deliberation
Decision aids should provide steps to assist the patient in
making a decision, which may include suggesting ways to
talk through the decision with health professionals and
include tools (worksheets or question lists) that would
allow discussion with others.11 Participants across all
groups stated that the identiﬁed steps for making a deci-
sion (a list of 6 items outlining the process) that were
highlighted in the decision aid (see ﬁgure 3) were a
helpful addition.
I think putting out how somebody might make a deci-
sion. You know, the six points [decision guidance]. And I
Figure 1 Example of content items from prototype trial decision aids: presenting probabilities section.
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think setting all of this… I was pleased that when I read it
through. (Ethics Committee Chair 4)
I do think that’s good; rather than giving them all the
information and then saying “Right, now it’s up to you to
make a decision.” it almost leads them through to actu-
ally think: right…it’s like making it a much more active
decision rather than just reading the leaﬂet and chucking
it away; their actually having to think about the questions
in their head. (Trial Manager 1)
There were also positive reactions to the ‘notes’ page
(included as a way to promote question asking and
deliberation, which was a blank page titled ‘notes’).
Participants felt this would facilitate the decision-making
process by enabling potential trial participants to ask
questions, highlight areas where they need more
support to make their decision and reﬂect on following
their decision-making.
And what I thought was excellent, and really this is great,
was that you gave room for notes, you know for patients to
make notes. It just gives permission for them to be able to
do that. And what I thought was, at every time point where
you’re maybe asking them to go through their decision,
put in a blank page which says ‘notes’, because I just think
that is really helpful and it facilitates them actually making
notes that they can return back to—“What was my think-
ing around this?” (Research Nurse 2)
In addition, members of all groups apart from the
Clinical Principal Investigators commented on aspects of
the decision aid being repetitive. One of the patients
stated the following with regard to the structured guid-
ance for decision-making:
Figure 2 Example of content
items from prototype trial decision
aids: methods for clarifying and
expressing values.
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It’s very clear. I would, the only comment I would make
on that is it’s probably repetitive of what’s gone on
throughout the whole book…But I wouldn’t say it would
drive me to take that away, not take it out. I just felt that,
you know, I’d read most of that and understood most of
1 to 6 in the preceding narrative. (Patient 1)
Experiences of other potential trial participants
Experiences of others (or patient stories) are sometimes
included in treatment decision aids and, if included,
should represent a range of experiences, both positive
and negative.11 Although there were mixed views
expressed, most thought the inclusion of other partici-
pants’ experiences was a helpful addition as the general
perception was that people are often interested in what
their peers have done and that this could help to nor-
malise trial participation.
It is like a big Expedia or a trip adviser thing, you are
always interested in the other people’s experiences. Yes
actually I think its something that we’ve not really
thought about before, that you are not alone here, that
there are hundreds and thousands and millions of
people participating in clinical trials all the time so to get
a wee bit of feedback from them, yes, yes no I like that.
(Research Nurse 1)
Some of the Research Nurse and Clinical Principal
Investigator participants reported that trial participants
often ask them what other patients have done and that
usually there is some dialogue around those
experiences.
Yeah, it’s [being asked what others think] not infrequent.
“What do your other patients think, Mr X?” I usually say,
“They often want to get involved.” “Oh, well okay then.” It’s
slightly interesting, and a bit bizarre, but there is a bit of
team play in that I think. (Clinical Principal Investigator 4)
They say, “What’s the uptake of others? Are they all
taking part or not?” And I say, “The majority take part in
a study; some don’t for various reasons. And some of
those reasons are personal to that patient: they’re too far
away, they don’t want to come back to the follow-up, they
hate hospitals, they don’t want to ever come back after
this—that type of thing.” (Research Nurse 4)
It was also highlighted that experiences of others may
enable participants to ask questions by highlighting
aspects they may not have previously been considered.
but what it at least does is it encourages them to ask ques-
tions because these guys have already identiﬁed experi-
ences that they have had. (Research Nurse 1)
Despite generally positive views about the inclusion of
others’ experiences, there were some queries raised
from Trial Managers and Research Nurses, with regard
to how the experiences from other trial participants
would be generated for inclusion in a trial decision aid
given that information leaﬂets are developed before any
participants have entered, or refused, the trial.
So I was a bit unsure how that was all going to work
because either you make it generic and it’s just about
patients who have participated in other trials, or you
wouldn’t be able to implement this for any trial until after
you’ve already got some patients in. (Trial Manager 4)
There was a concern from one respondent (an Ethics
Committee Chair) who perceived there to be no add-
itional value by including experiences of others and that
it complicated the process by introducing the perspec-
tives of others when ultimately the decision lies with that
individual and should be based on their own values and
preferences.
[I’m] Not sure it doesn’t… just that it doesn’t cloud the
water, it was their decision at the end of the day. (Ethics
Committee Chair 5)
Amount of information
There was variation in participants’ perceptions about
the amount of information and the length of the trial
decision aids, with the majority of stakeholders (largely
Trial Managers, Ethics Committee Chairs and Principal
Investigators agreeing there was too much information
and others (patients and Research Nurses)feeling all of
the information included was important. There was rec-
ognition that the length could be partially attributed to
the prespeciﬁed regulatory requirements. None of the
patients felt there was too much information or that the
trial decision aids were too long. For example:
I can’t say that I found anything in the book unhelpful.
(Patient 3)
Figure 3 Example of content items from prototype trial
decision aids: structured guidance in deliberation:
decision-making steps. (adapted from Juraskova et al13)
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Its difﬁcult because there is so much stuff that is legis-
lated that has to be in, so it is difﬁcult to condense them
any less. (Research Nurse 2)
Method of delivery
The stakeholders in this study had varying preferences,
which diverged between and within groups, for how the
trial decision aids should be delivered. Some felt that
there should be a move towards presenting this type of
information online or using other electronic media such
as DVDs. However, others felt that providing the informa-
tion in a booklet format was the best option as this allows
people to take it away with them and discuss with others.
You know, if there were a DVD of somebody talking me
through this with the diagrams, the presentation, which
they could look at in the research room, that would be
much better. I’m sure that would be more acceptable to
most of them [trial participants]. (Clinical Principal
Investigator 4)
I read it quite thoroughly from page to page, and I think
that’s what it’s designed to do, you can take time to read
it and make some notes and then consult with somebody
else about it, you know? I think the paper document is
the best way; the old-fashioned way is the best way, really.
(Patient 2)
Some reported that the speciﬁc method of delivery is
less important and more emphasis should be placed on
accessibility.
I think it’s important that whatever you use people can
access it easily and that if they choose to they can show it
to other people outside the place or the room where
they made the decision, so they can go over it again.
(Ethics Committee Chair 4).
However, participants in the Research Nurse, Trial
Manager and Ethics Committee Chair groups identiﬁed
the importance of context with regard to the trial popu-
lation being recruited.
Some people were put off by it [computer tablet], but
that is just my client group [elderly]. Obviously it is going
to really depend on you client group, if it is children,
teenagers, people in their twenties, thirties, forties, that’s
how we live our lives, that is how we expect to receive
information nowadays. We certainly don’t expect to get it
in a paper format. (Research Nurse 2)
The untapped potential of trial participation decision aids
The interviews also focused on participants perceptions
of the future potential of decision aids to support deci-
sions about participation. Participants’ reﬂections on this
were varied, ranging from improving consent (across all
stakeholders) through to increasing recruitment (men-
tioned by Clinical Principal Investigators and Research
Nurses) and retention (highlighted by Research Nurses,
Clinical Principal Investigators and Trial Managers) in
the trial. However, stakeholders across all groups high-
lighted a focus on the biggest potential gains to be from
improving aspects of the decision-making process such as
informedness (which includes an understanding of their
involvement and commitment to the trial over time) and
opportunities for discussion with others.
To me, it was still open [the decision] right the way
through…. But reading this here, right the way through
the whole thing you’re still feeling, “Well there’s still an
option, they’re still making sure it’s ok. (Patient 1).
So I think a tool like this ought and should help people
make a better decision, fully informed decision that they
can also explain to perhaps their own clinician, certainly
to family and friends. (Ethics Committee Chair 3)
I think it’s probably making the patient more aware of
what’s actually involved, and what the commitment will
be from the patient. (Trial Manager 1)
There was also recognition, largely by Trial Managers
and Research Nurses, that these trial decision aids have
the potential to actively engage potential participants in
their decision-making process and allow them to make
personally relevant decisions that they are able to discuss
with others.
…it makes it a bit more personalised, it makes them
think about how they would cope with this trial in their
life at the time, then I think that would be useful, it
would maybe help them think, ‘Am I really going to
manage this?. (Trial Manager 5)
To empower for decision making, to enfranchise them to
make a decision, and to not just get people on study, but
to care for people when they’re on study, in that this is
more helpful to know that they have made a truly well
informed decision. And it’s something about giving
patients the ownership of what they’re doing, and I think
this is helpful in that. (Research Nurse 5)
DISCUSSION
Principal findings
This is one of the ﬁrst studies to explore perceptions
about the potential of decision aids to support decisions
about trial participation from the perspective of all key
stakeholder groups and provides empirical data on a
range of relevant stakeholder perspectives. Furthermore,
this is the ﬁrst study to explicitly investigate stakeholders’
views about key content items of decision aids and their
appropriateness for decisions about trial participation.
Overall, stakeholders felt that the decision aids were an
improvement on existing PILs in that they explicitly
highlighted that there was a decision to be made about
participation in the trial. In addition to this, stake-
holders believed that the decision aids also provided
ways for potential participants to engage with the
decision-making process and make personally appropri-
ate decisions for them as individuals.
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This study explored views about the speciﬁc content
items that differ between decision aids and existing PILs
namely: provision of information about positive and
negative features of options; presenting probabilities;
methods for clarifying and values; structured guidance
in deliberation; and experiences of other potential trial
participants. It is important to highlight that while the
majority of the stakeholders agreed on speciﬁc aspects
there were some key differences between the patient
group versus the others. For example, patients views dif-
fered to the majority of other stakeholders groups with
regard to provision of information about positive and
negative features of taking part in a trial (speciﬁcally
with regard to the exacting information contained
within the section) in that patients felt it to be balanced
but others reported worries about coercive language. In
addition, many of the stakeholders felt that the decision
aids were too long, but none of the patients reported
this with all of them saying that all of the information
was important. These ﬁndings (which must be consid-
ered within the context of this study ie, patients may be
different the general population) should serve as a
reminder that when developing decision aids for trial
participation, while all stakeholder views are important,
patients views must be placed at the core.
In principle, the general concept of providing infor-
mation about positive and negative features of options
(ie, to participate or not) was received positively and was
felt to provide balance to the decision by highlighting
all features. However, some participants expressed views
that some of the language was weighted, or may allow
participants to attach value to, and could be deemed as
potentially coercive. Therefore, it would be important in
future decision aids for trial participation to ensure that
neutral statements are incorporated. A recent study has
illustrated the potential bias that can be introduced into
trial participants’ decision making when the framing
effects of language are not addressed.23
The section on presenting probabilities was well
received by all stakeholders and was stated to be an
improvement on current PILs. However, it served to
further highlight that individuals have preferences for
the way probabilistic information is presented and that
there is no ‘one size ﬁts all’ approach. This is of par-
ticular importance when considering that understand-
ing and perception of risk within clinical trials can be a
signiﬁcant inﬂuence on the decision to take part or
not.24 Although there is a wealth of literature on how
best to communicate probabilistic information in a
treatment and screening context, this does not exist for
decisions about trial participation where often due to
the inherent nature of trials, much of this information
is not known and the layers of risk are greater (eg, risk
of the trial vs risk of treatment, risk of outcomes asso-
ciated with both interventions, risk of randomisation,
etc). Therefore, further research to identify how this
can be undertaken effectively, in different trial con-
texts, are of importance.
The values clariﬁcation exercise was reported as a posi-
tive addition and provided a way to engage potential par-
ticipants in their decision making by making them
weigh up what matters most to them. One study has
measured the extent to which the use of values clariﬁca-
tion exercises support (hypothetical) decisions about
trial participation and found they lowered ambivalence
and decisional uncertainty while improving the clarity of
personal values.15 Therefore, there is merit in further
exploring this type of exercise to support decisions with
potential trial participants facing real decisions.
The section on experiences of others was well received
by most stakeholders, with several saying that potential
participants already ask for this type of information.
Participant stories about trial participation are already
available through public websites such as healthtalkon-
line and the NIH clinical trials website.25 26 However, as
yet there is no evidence as to the beneﬁt or harm of
including this type of information on people’s decision-
making. While patient stories may be an effective way to
increase engagement with the information, there are
concerns that people will make decisions based on
others values rather than their own.27 As such, further
research is required to determine whether and how they
can be used in this context.
None of the patient group expressed the view that
there was too much information incorporated, a ﬁnding
mirrored by an earlier study exploring patients percep-
tions of a trial decision aid for radiotherapy for prostate
cancer.14 However, most of the other stakeholder groups
thought the decision aids might be too long. Some sta-
keholders attributed the amount of information to the
guidance requirements for content of informed consent
information and recognised this as a barrier against
keeping information materials concise. A recent review
highlighted the lack of evidence, from a participant’s
perspective, to support inclusion of many of these pre-
requisite items in trial information.28 However, within
the context of a decision aid, stakeholders have agreed
that many items required for informed consent (as
deﬁned by the regulatory guidance) and items required
for informed decision-making (as deﬁned by the
International patient decision aid standards) are import-
ant and should be included.20 Therefore, ways of pre-
senting this information more succinctly need to be
explored alongside real-time decision-making by real
patients to explore which information is most valued.
The Ottawa Decision Support Framework (ODSF)
recommends that during the development and piloting
process for decision aids, end users are engaged and
their preferences for delivery of the intervention are
incorporated.29 During this study we elicited partici-
pants’ views with regard to the most appropriate method
of delivery. Stakeholders’ perceptions varied in this
regard, with some believing that online or electronic
methods were best and others believing paper based was
optimal but certainly the context and preferences of the
end users should be considered. Other studies have
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shown that patients deliberating informed consent for
elective surgery had preferences for methods of infor-
mation provision, with younger patients preferring
internet-based information and older patients preferring
paper-based information30 providing further justiﬁcation
for engaging with users at the outset. However, it should
be highlighted that a recent systematic review found
equivocal evidence with regard to effectiveness of audio–
visual interventions to enhance trial knowledge (during
informed consent) but the authors highlight the need
to involve consumers in intervention development.31
These ﬁndings are important for development of deci-
sion aids but also for PILs more generally. As such, trial
participants and trial staff (eg, Research Nurses,
Clinician Principal Investigators) should be engaged
during development of trial decision aids to ascertain
the best mode of delivery in the trial population.
Moreover, if the mode of delivery is novel it may also be
worth engaging with ethics committees early in the
process.
Overall, these ﬁndings complement the previous pre-
liminary work on decision aids for trial participation in
that they show that patients perceive these tools as useful
and more helpful (compared to existing PILs) in terms
of making a well-informed, balanced, personally relevant
decision.13 14 However, our results also contribute add-
itional insights through the involvement of a wide range
of stakeholders, which include perspectives from those
involved in developing, delivering and reviewing infor-
mation for patients considering trial participation.
Moreover, these ﬁndings contribute to the wider litera-
ture on participants and stakeholders sense-making of
research participation with respect to what it means for
them as individuals. For example, a study by Townsend
and Cox identiﬁes the importance of the ‘meaning’ of
research participation (including trials) for participants,
implicitly underpinned by their individualised context
and which transcend the entire participation trajectory,
not just the point of consent.32
Strengths and weaknesses
A signiﬁcant strength of this study was the elicitation of
views from a diverse stakeholder group, including:
patients; Research Nurses; Trial Managers; Clinical
Principal Investigators; and Ethics Committee Chairs.
This forms of multistakeholder engagement is promoted
as international best practice by the ODSF. Two other
studies have explored perceptions of decision aids for
trial participation and highlighted their potential
beneﬁt, but this previous work has focused only on
patients.13 14 While patient perceptions are key, as they
are the decision-makers, it is important to explore the
views of others involved in the informed consent process
who would be responsible for developing, endorsing,
reviewing and delivering these decision aids. Many of
the barriers to implementation of decision aids for treat-
ment decisions relate to ‘process’ aspects, which may be
less relevant for trial decision aids due to a regulatory
requirement to provide information in the informed
consent process. As such, decision aids for trials would
slot in to the existing informed consent process but
would require additional training of those delivering to
ensure ﬁdelity of use. However, if there is a lack of
buy-in and endorsement from those involved in the
informed consent process, the decision aids may not be
implemented as intended that is, tools to support
decision-making that also enable conversations about
treatment (and in this context trial participation) to be
created and discussed in a meaningful way. Therefore, it
is critical to engage with end-users during development.
A further strength of this study was the decision to
explore stakeholders’ perceptions of key decision aid
content items a priori, rather than exploring only
general perceptions. This is of particular importance
when considering that it is these items which deﬁne
decision aids as being different to existing PILs.
It may be that the speciﬁc trial contexts may have
inﬂuenced participants’ perceptions of the decision
aids. However, several sections were written from a
generic perspective and were not speciﬁc for the individ-
ual trial context, which included both a chronic and an
acute condition. Moreover, the majority of the stake-
holder groups (Research Nurses, Trial Managers and
Ethics Committee Chairs) were not directly involved
with the trials in which the decision aids were set and
the data suggest that their perceptions were being con-
sidered commonly across decision aids more widely
rather than the exacting information for each trial pilot
decision aid presented. All the participants in our study
were UK based and therefore may hold different views
to those in other countries with different social norms
and cultures. However, it was felt that focusing on the
UK was appropriate due to the differences in regulatory
requirements and structure of PILs across countries, that
is, consent forms for American and Canadian studies
tend to be longer than UK forms and contain much of
the information being found within UK PILs. In add-
ition, there was an assumption that these decision aids
were for adults who had capacity to consent for them-
selves. It would also be important to explore the useful-
ness of these tools in other contexts with proxy
decisionmakers, including parent of children who are
consenting on their behalf. Another potential limitation
of our study is that the sample were a self-selecting
group of individuals and, especially for the patients, may
be different from those in the general population.
Indeed the size of each of the stakeholder groups was
relatively small. However, it is important to highlight that
the participants included in this study can offer thought-
ful and reﬂective insights into decision aids for trial par-
ticipation when reﬂecting on their own trial experience
including reﬂection on existing PILs.
Implications for researchers
Decision aids for trial participation should be developed
with meaningful stakeholder involvement. All aspects of
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the information should be balanced. Attention to lan-
guage is critical to ensure it is not deemed coercive or
value laden. Developers should be mindful of the target
audience, especially when considering presenting prob-
abilistic information and considering method of delivery.
If patient stories are included, how these will be gener-
ated and included must be considered. Finally, decision
aids for trial participation should be developed and used
in ways that allow all users to engage effectively with the
information and provide support to decision-makers.
Future research
While the decision aids explored in this study were per-
ceived as being potentially helpful, it should be noted
that these types of interventions (or certainly the aids
developed in this study) may be more appropriate to
support some RCT decisions than others, we are not
proposing a ‘one size ﬁts all’ model. It is likely that deci-
sion aids could be more effective for some trial decisions
rather than others for example, where interventions
being trialled are very different (like medical manage-
ment vs surgery), which is also the case for treatment
decision aids.10 It may also be that the decision aid
could be broken up into component parts (values clariﬁ-
cation exercises, experiences of others, etc) and used as
appropriate (deﬁned by individuals preferences for
information) in different contexts to facilitate and
support the informed decision-making process.
However, this requires further evaluation before recom-
mendations can be made.
In addition, given the limitations of the current con-
ceptualisation of informed consent, it is important to
think about how decision aids would be evaluated. For
example, if tested in an RCT against existing PILs what
outcomes should be measured, how do these outcomes
compare to others in existing studies of interventions to
improve consent, and what do potential participants
think should be measured?
Further research regarding how decisions about trial
participation are discussed, engaged with, deliberated
over, participated in, supported and executed is required
to inform the design of interventions to better support
the process. In addition, where much of the previous lit-
erature has focused on participants’ understanding of
trial concepts such as randomisation and blinding,
exploration of what participants believe taking part
means for them as individuals could also help to
develop more tailored approaches to informed consent.
CONCLUSIONS
Compared to existing PILs, decision aids for trial partici-
pation have the potential to promote a more ‘informed’
decision-making process with regard to consent. It is
vital that research efforts, inclusive of all stakeholders,
continue to understand how to support potential trial
participants’ decisions about trial participation (whether
it be to enroll or not); how to ensure these decisions are
in line with individuals values and preferences and to
determine optimal methods to support informed
decision-making in this context.
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